NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $5.12 +0.04 (+0.79%) (As of 09/18/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Capricor Therapeutics alerts: Email Address About Capricor Therapeutics Stock (NASDAQ:CAPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$5.02▼$5.6050-Day Range$3.56▼$5.1252-Week Range$2.68▼$7.28Volume815,820 shsAverage Volume348,288 shsMarket Capitalization$163.73 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingBuy Company OverviewCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More… War on Elon Escalates… (Ad)Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.Click here to learn how you can benefit from its widespread distribution. Capricor Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 31st PercentileCapricor Therapeutics scored higher than 31% of companies evaluated by MarketBeat, and ranked 841st out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.24) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -5.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 7.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.36% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 6.71%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted23.36% of the outstanding shares of Capricor Therapeutics have been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 6.71%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.45 News SentimentCapricor Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Capricor Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.00% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Stock News HeadlinesCapricor Therapeutics Poised for Growth with Expanded Deramiocel Partnership and Positive Phase 3 OutlookSeptember 18 at 7:00 PM | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Receives "Buy" Rating from HC WainwrightSeptember 18 at 3:57 AM | americanbankingnews.comWar on Elon Escalates… Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.September 18, 2024 | Porter & Company (Ad)Capricor Therapeutics (NASDAQ:CAPR) Stock Quotes, Forecast and News SummarySeptember 18 at 3:56 AM | benzinga.comCapricor Therapeutics partners with Nippon Shinyaku for European commercialization of DeramiocelSeptember 18 at 3:56 AM | msn.comBuy Rating Affirmed for Capricor Therapeutics Amidst Expanded Partnership and Regulatory AdvancementsSeptember 18 at 3:56 AM | markets.businessinsider.comCapricor Collaborates With Nippon Shinyaku For European Expansion Of Deramiocel For DMD; Stock UpSeptember 18 at 3:56 AM | markets.businessinsider.comEXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma FirmSeptember 18 at 3:56 AM | benzinga.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $4.89 on January 1st, 2024. Since then, CAPR shares have increased by 4.7% and is now trading at $5.12. View the best growth stocks for 2024 here. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) released its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $0.03. The biotechnology company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative trailing twelve-month return on equity of 220.27% and a negative net margin of 102.93%. Who are Capricor Therapeutics' major shareholders? Top institutional shareholders of Capricor Therapeutics include Renaissance Technologies LLC (0.43%), Marshall Wace LLP (0.28%), Bank of New York Mellon Corp (0.25%) and Rhumbline Advisers (0.10%). Insiders that own company stock include David B Musket, Paul Gisbert Auwaerter and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN) and Dynavax Technologies (DVAX). Company Calendar Last Earnings8/07/2024Today9/18/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CAPR CUSIPN/A CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$40.00 Low Stock Price Target$8.00 Potential Upside/Downside+290.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,290,000.00 Net Margins-102.93% Pretax Margin-102.93% Return on Equity-220.27% Return on Assets-60.88% Debt Debt-to-Equity RatioN/A Current Ratio1.37 Quick Ratio1.37 Sales & Book Value Annual Sales$27.15 million Price / Sales6.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book7.01Miscellaneous Outstanding Shares31,979,000Free Float28,142,000Market Cap$163.73 million OptionableOptionable Beta3.92 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:CAPR) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredCrypto ‘Banana Zone’ Incoming…What if I told you that bananas could make you a millionaire? No, this isn't a joke – I'm talking about the...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.